The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Lucentis (ranibizumab) be listed on the Pharmaceutical Benefits Schedule (PBS) for the treatment of proliferative diabetic

Glaucoma affects over 300,000 Australians, with nearly half of these people unaware they have the disease until irreversible significant vision loss has occurred. As

Australian health innovators, companies, entrepreneurs and researchers have been invited to make submissions to the Taiwan Trade Centre’s ‘Go Healthy with Taiwan’ campaign.

Applications are invited for the Ophthalmology Star Awards, celebrating individuals who have made outstanding contributions to ophthalmology.